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A B S T R A C T
Background
Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological
malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer treatment.
Objectives
To evaluate the effectiveness and morbidity associated with ultra-radical/extensive surgery in the management of advanced stage ovarian
cancer.
Search methods
We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library 2010, Issue 4), MEDLINE and EMBASE (up to November 2010). We also searched registers of clinical trials,
abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.
Selection criteria
Randomised controlled trials (RCTs) or non-randomised studies, analysed using multivariate methods, that compared ultra-radical/
extensive and standard surgery in adult women with advanced primary epithelial ovarian cancer.
Data collection and analysis
Two review authors independently assessed whether potentially relevant studies met the inclusion criteria, abstracted data and assessed
the risk of bias. One non-randomised study was identified so no meta-analyses were performed.
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Main results
One non-randomised study met our inclusion criteria. It analysed retrospective data for 194 women with stage IIIC advanced epithelial
ovarian cancer who underwent either ultra-radical (extensive) or standard surgery and reported disease specific overall survival and
perioperative mortality. Multivariate analysis, adjusted for prognostic factors, identified better disease specific survival among women
receiving ultra-radical surgery, although this was not statistically significant (Hazard ratio (HR) = 0.64, 95% confidence interval (CI):
0.40 to 1.04). In a subset of 144 women with carcinomatosis, those who underwent ultra-radical surgery had significantly better disease
specific survival than women who underwent standard surgery (adjusted HR = 0.64, 95% CI 0.41 to 0.98). Progression-free survival
and quality of life (QoL) were not reported and adverse events were incompletely documented. The study was at high risk of bias.
Authors’ conclusions
We found only low quality evidence comparing ultra-radical and standard surgery in women with advanced ovarian cancer and
carcinomatosis. The evidence suggested that ultra-radical surgery may result in better survival. It was unclear whether there were any
differences in progression-free survival, QoL and morbidity between the two groups. The cost-effectiveness of this intervention has not
been investigated. We are, therefore, unable to reach definite conclusions about the relative benefits and adverse effects of the two types
of surgery.
In order to determine the role of ultra-radical surgery in the management of advanced stage ovarian cancer, a sufficiently powered
randomised controlled trial comparing ultra-radical and standard surgery or well-designed non-randomised studies would be required.
P L A I N L A N G U A G E S U M M A R Y
Ultra-radical surgery for women with advanced ovarian cancer
Ovarian cancer is the commonest cause of death in women with a female cancer. Opinions differ about whether women with advanced
ovarian cancer do better if they have ’ultra-radical’ surgery which is much more extensive than standard surgery.
We systematically searched the scientific literature for reports of studies comparing ultra-radical and standard surgery for women
with advanced ovarian cancer. We looked for randomised controlled trials, which are regarded as the best type of study, and for non-
randomised studies that were analysed using methods that allow for differences between the groups of women receiving different types
of surgery.
We found only one relevant non-randomised study. It analysed data for 194 women recruited at one centre. Analysis that allowed
for the differences in the extent of disease of the women who received the two different types of surgery found better disease specific
survival among women receiving ultra-radical surgery. The best estimate was that their risk of death from ovarian cancer was about one
third lower than for women who had standard surgery, but it might actually have been anywhere between 60% lower and 4% higher.
However, the extent of disease in these women varied a lot so the authors also analysed only the 144 women whose cancer had spread
throughout their abdomen. Again, the best estimate was that their risk of death was about one third lower than for women who had
standard surgery, but it might have been anywhere between 60% lower and only 2% lower. Although this result seems to suggest that
ultra-radical surgery might be better than standard surgery, we need to be cautious as the study was not well designed nor analysed, so
it may be over-estimating the real benefits of ultra-radical surgery.
The study did not report all deaths, which would have been a more reliable and more important outcome. Neither did it report any
differences between the groups in the time before the cancer progressed. It did not report quality of life (QoL) which would be very
important to women with this advanced cancer. The cost-effectiveness of this intervention was not investigated.
Therefore, we could not reach any definite conclusions about the relative benefits and adverse effects of the two types of surgery. Better
designed, large studies are needed in order to compare ultra-radical and standard surgery for women with advanced ovarian cancer.
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B A C K G R O U N D
Description of the condition
Ovarian cancer is the sixth most common cancer among women
and the leading cause of death in women with gynaecological
malignancies. Globally, there are over 200,000 new cases per year,
with approximately 6.6 new cases per 100,000 women per year. A
woman’s cumulative risk of developing ovarian cancer by the age
of 65 years is 0.5%: 0.4% in less developed countries and 0.7%
in more developed countries (Ferlay 2004). It is less common in
women under the age of 35 years, and its incidence increases with
age. In Europe, approximately 37% of women with ovarian cancer
are alive five years after diagnosis (EUROCARE 2003), largely
because the early stages of the disease often present with very few,
if any, specific symptoms so most women present with advanced
stage disease (Jemal 2008; Kurman 2008; Lancet 2007; Visintin
2008).
Cancers of the ovary are classified according to their cells of origin.
Most ovarian cancers originate from the surface (epithelial) cells
of the ovary and are termed epithelial tumours, although some
cancers can also arise from the substance of the ovary, called stro-
mal tumours, or from embryological differentiation (sex cord and
germ cell tumours). The staging of ovarian cancer is based on the
International Federation of Gynaecology and Obstetrics (FIGO)
classification system (Shepherd 1989). FIGO staging depends on
the findings at the time of surgery. Stages I and II constitute early
stage disease, where Stage I is limited to the ovaries and Stage
II tumours extend to the pelvis. Stages III and IV constitute ad-
vanced disease. In Stage III the tumour extends outside the pelvis,
or involves lymph nodes within the pelvis, and Stage IV is where
the tumour has spread to distant sites such as the liver, lungs and
lymph nodes in the neck.
Description of the intervention
A common and popular treatment for the management of women
with epithelial ovarian cancer is surgery followed by combination
platinum and taxane based chemotherapy (Ozols 2003). Prognosis
depends not only on the stage and histological type of the tumour
but also the end result of surgery. Studies have shown that resid-
ual disease after initial surgery is a strong independent prognostic
factor for survival, with improvements in both overall and pro-
gression free survival being greatest in women with no (currently
termed complete cytoreduction) or minimal ( < 1 cm, currently
termed optimal cytoreduction) visible residual disease at the end
of surgery (Aletti 2006; Eisenhauer 2006). Women who undergo
more extensive surgery are more likely to have tumour deposits
of ≤ 2 cm at the end of surgery (Crawford 2005), while each
10% increase in maximal cytoreduction appears to be associated
with a 5.5% increase in median survival time (Bristow 2002). The
five-year survival for patients having surgery that leaves residual
tumour deposits of more than 2 cm and surgery with residual
tumour deposits of up to 2 cm at the end of the procedure are
similar, further suggesting that optimal cytoreduction is associated
with improved survival rates (Bristow 2002). However, the extent
of surgical resection required to achieve optimal cytoreduction re-
mains controversial. There appears to be a universally diverse prac-
tice with huge variations in the cytoreduction rate of between 22
to 98% (Bristow 2002; Eisenkop 1998).
Although there is a lack of evidence demonstrating a benefit from
performing a hysterectomy at the time of debulking surgery, this
is accepted practice as it aids the diagnosis of a primary tumour
site, for example, serous papillary cancers and mixed mullerian
tumours may originate from both the uterus and ovary. It also
helps in excluding synchronous primary uterine tumours. While
systematic lymphadenectomy may not be standard practice in cy-
toreductive surgery for ovarian cancer, removing the uterus and
cervix, both tubes and ovaries, the omentum and enlarged lymph
nodes is part of standard surgery (Aletti 2006; Todo 2003).
Patients with widespread disease that is those with upper abdom-
inal disease affecting the diaphragm, liver, spleen and omentum,
or widespread disease affecting the bowel, will need much more
radical surgery in order to achieve complete or optimal cytore-
duction. The complexity of the procedures required to achieve
these outcomes undoubtedly increases. Radical surgery including
bowel resection, splenectomy, liver resection and diaphragmatic
stripping has been described in the literature as treatment for ad-
vanced ovarian cancer with low complication rates (Bristow 2003;
Eisenkop 2001a; Jaeger 2001;Merideth 2003;Montz 1989). Stan-
dard and ultra-radical (extensive) surgery are a continuum, and
three types of surgery or procedures have been defined. These are
standard surgery, which comprises, as a minimum, hysterectomy,
bilateral adnexectomy with excision of the pelvic peritoneum, to-
tal omentectomy including the supracolic omentum, appendicec-
tomy, removal of bulky pelvic and lumbo-aortic nodes +/- simple
peritonectomies; 2) radical surgery comprising in addition to the
above mentioned elements, en bloc removal of the uterus, both
ovaries, the pelvic peritoneum and recto-sigmoid with or with-
out simple peritonectomies; and 3) supra-radical surgery, that is,
a radical procedure plus at least one of the following: a) exten-
sive peritonectomies including partial resection of the diaphragm,
b) resection of subcapsular liver metastases, cholecystectomy, c)
splenectomy, resection of that tail of the pancreas and d) other
bowel resection, partial gastrectomy, etc. (Pomel 2004).
It has been proposed that multiple factors including tumour biol-
ogy determine themanner of disease progression, which in turn in-
fluences the likelihood of surgical cytoreduction (Eisenkop 2001a;
Hoskins 1992;Markman2007). Supporters of non-radical surgery
argue that the initial extent of advanced disease reflects the ag-
gressiveness of the tumour, and ultimately dictates treatment suc-
cess. Therefore, when radical surgery becomes necessary to achieve
optimal cytoreduction, it may not improve survival despite leav-
ing minimal residual disease (Covens 2000). Furthermore, the
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role of surgery has been questioned because patients who undergo
complete cytoreduction and have better survival often represent
women who have relatively small pre-operative tumour loads and
therefore less biologically aggressive tumours, and that differences
in tumour biology account for the survival benefits that are re-
ported to be from surgery (Eisenkop 1998; Hoskins 1992). Per-
haps of greater concern is the patient morbidity that is incurred
during such radical procedures, both in the perioperative and post-
operative periods (Chen 1985; Van Dam 1996; Venesmaa 1992).
Furthermore, several authors have reported that patients who un-
derwent extensive debulking procedures such as bowel resection
and peritoneal stripping did not have a survival advantage com-
pared with those patients who did not undergo such procedures
and had residual disease remaining (Potter 1991).
In showing that survival outcomes of extensive disease managed
by ultra-radical (extensive surgery) is equivalent to less extensive
disease managed by less radical surgery, whereby complete cytore-
duction is being achieved in both cases, would be supportive of
the value of cytoreduction in negating the adverse effects of aggres-
sive tumour biology on outcome survival. Also by having equally
extensive disease and managing some by ultra-radical (extensive)
surgery and some by standard surgery and showing an improve-
ment in survival outcome with ultra-radical surgery would also be
supportive of the benefits of cytoreduction.
As would be expected, ultra-radical surgery is associated with a
prolonged operating time and exposure to anaesthesia. This in-
creases the risk of hypothermia, respiratory complications such as
atelectasis (lung collapse), infection, adult respiratory distress syn-
drome, blood loss and intraoperative ureteric, bowel and bladder
injury. In the postoperative period, these women may require a
longer hospital stay and recovery time, with an increased risk of
infection (chest, wound, urine), venous thromboembolic disease,
poorer mobility and poorer nutritional status. The cost effective-
ness of such surgery would also require evaluation.
Why it is important to do this review
To our knowledge, there have been no previous systematic reviews
on ultra-radical (extensive) surgery versus standard surgery. In a
survey of members of the Society of Gynecologic Oncologists,
45.5% of surgeons cited the lack of evidence for improved sur-
vival as a primary rationale against performing aggressive surgical
resection (Eisenkop 2001b). Given the differences in opinion re-
garding the role of extensive debulking surgery in ovarian cancer
treatment, the aim of this review was to examine the available ev-
idence for ultra-radical surgery in ovarian cancer management.
O B J E C T I V E S
To evaluate the effectiveness and morbidity associated with ultra-
radical (extensive) surgery in the management of ovarian cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs)
As we expected to find few if any RCTs of surgical interventions
(Johnson 2008), the following types of non-randomised studies
with concurrent comparison groups were included.
• Quasi-randomised trials, non-randomised trials,
prospective and retrospective cohort studies, and case series of
100 or more patients.
Case-control studies, uncontrolled observational studies and case
series of fewer than 100 patients were excluded.
In order to minimise selection bias, we decided to include only
studies that used statistical adjustment for baseline case mix (for
example age, performance status, grade, etc) using multivariate
analyses.
Types of participants
Adult women diagnosed with Stages III and IV epithelial ovarian
cancer. Women having ultra-radical surgery as part of interval
debulking surgery (surgery halfway through the course of chemo-
therapy) were included.
Women with other concurrent malignancies were excluded.
Women with recurrent disease were also excluded.
Types of interventions
• Intervention: ultraradical surgery defined as total
abdominal hysterectomy, bilateral salpingo-öophorectomy,
omentectomy, removal of enlarged lymph nodes (para-aortic,
pelvic, obturator) and one or more of the following: upper
abdominal surgery (splenectomy, diaphragmatic or peritoneal
stripping, liver resection), bowel surgery or stoma formation or
urinary tract surgery
• Comparison: standard surgery defined as total abdominal
hysterectomy, bilateral salpingo-öophorectomy, omentectomy
either with or without removal of enlarged lymph nodes (para-
aortic, pelvic, obturator), and debulking of any other superficial
tumour plaques.
The types of interventions defined above have been widely de-
scribed in the literature and have been adapted from the paper
on management of malignant epithelial tumours of the ovary by
Pomel 2004.
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Types of outcome measures
Primary outcomes
1. Overall survival: survival until death from all causes.
Survival was assessed from the time when women were enrolled
in the study.
Secondary outcomes
1. Progression-free survival.
2. Optimal cytoreduction, defined as residual tumour <1 cm,
or complete cytoreduction.
3. Death within 30 days of intervention.
4. Adverse events classified according to CTCAE 2006:
i) direct surgical morbidity: e.g. vascular injury, injury to
bladder, ureter, small bowel or colon, presence and complications
of adhesions, febrile morbidity, intestinal obstruction,
anastomotic leak, haematoma, collection, local infection.
ii) surgically related systemic morbidity e.g. chest/wound/
urine infection, thrombo-embolic events (deep vein thrombosis
and pulmonary embolism), cardiac events (cardiac ischaemia,
myocardial infarction and cardiac failure), cerebrovascular
accident, transfusion reaction, pulmonary oedema;
iii) recovery: delayed discharge, unscheduled re-admission
5. Quality of life (QoL) measured using a scale that has been
validated through reporting of norms in a peer-reviewed
publication.
Search methods for identification of studies
Papers in all languages were sought and translations carried out
when necessary.
Electronic searches
See: Cochrane Gynaecolgical Cancer Group methods used in re-
views.
The following electronic databases were searched.
• The Cochrane Central Register of Controlled Trials
(CENTRAL), (The Cochrane Library 2010, Issue 4).
• The Cochrane Gynaecological Cancer Collaborative
Review Group’s Trial Register
• MEDLINE up to November 2010
• EMBASE up to November 2010
The MEDLINE, EMBASE and CENTRAL search strategies
based on terms related to the review topic are presented in
Appendix 1, Appendix 2 and Appendix 3 respectively.
Databaseswere searched from January 1966untilNovember 2010.
All relevant articles found were identified on PubMed and using
the ’related articles’ feature, a further search was carried out for
newly published articles.
Searching other resources
Unpublished and grey literature
Metaregister, Physicians Data Query, www.controlled-trials.com/
rct, www.clinicaltrials.gov and www.cancer.gov/clinicaltrials were
searched for ongoing trials.
Reference lists
Reference lists of all included studies were searched for additional
studies.
Handsearching
Abstracts of meetings from the International Gynaecological Can-
cer Society (2000 to 2008), the British Gynaecological Cancer
Society (2008), European Society of Gynaecological Oncology
(2003, 2005 and 2009) and the Society of Gynecologic Oncolo-
gists (2009 and 2010) were handsearched to identify unpublished
studies.
Data collection and analysis
Selection of studies
All titles and abstracts retrieved by electronic searchingwere down-
loaded to the referencemanagement database Endnote, duplicates
were removed and the remaining references were examined by
two review authors (CA, KC) independently. Those studies which
clearly did notmeet the inclusion criteria were excluded and copies
of the full text of potentially relevant references were obtained.
The eligibility of retrieved papers was assessed independently by
two review authors (CA, KC). Disagreements were resolved by
discussion between the two review authors and when necessary by
a third and fourth review authors (AB, RN). Reasons for exclusion
were documented.
Data extraction and management
For included studies, data were abstracted as follows.
• Author, year of publication and journal citation (including
language).
• Country.
• Setting.
• Inclusion and exclusion criteria.
• Study design, methodology.
• Study population, the following will be abstracted by
treatment arm if possible:
• ◦ total number enrolled.
◦ patient characteristics.
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◦ age.
◦ ethnicity.
◦ co-morbidities.
◦ response to neo-adjuvant chemotherapy.
• Ovarian cancer details at diagnosis:
◦ FIGO stage (III or IV).
◦ histological cell type.
◦ differentiation.
• Previous treatment (neoadjuvant chemotherapy subgroup
analysis: responders versus non-responders).
• Surgical details:
◦ type of surgeon (Gynaeoncologist, Gynaecologist,
General surgeon).
◦ type of surgery (ultra-radical (extensive) versus
standard).
• Risk of bias in study (see below).
• Duration of follow-up.
• Outcomes (see above) - overall survival, progression-free
survival, QoL and adverse events.
◦ For each outcome: outcome definition (with
diagnostic criteria if relevant).
◦ unit of measurement (if relevant).
◦ for scales: upper and lower limits, and whether high or
low score is good;
◦ For results: Number of participants allocated to each
intervention group.
◦ for each outcome of interest: Sample size; Missing
participants.
We abstracted the hazard ratio and its 95% confidence interval.
For adjusted statistics, we noted the variables used in adjustment.
Where possible, all data extracted were those relevant to an in-
tention-to-treat analysis, in which participants were analysed in
groups to which they were assigned. The time points at which
outcomes were collected and reported was noted.
Data were abstracted independently by two review authors (CA,
KC) onto a data abstraction form specially designed for the review.
Differences between review authors were resolved by discussion or
by appeal to a third review author (AB), when necessary.
Assessment of risk of bias in included studies
The risk of bias in included studieswas assessed using theCochrane
Collaboration’s tool (Higgins 2008). This included assessment of:
• sequence generation;
• allocation concealment;
• blinding (where assessment of blinding was restricted to
blinding of outcome assessors, since it is generally not possible to
blind participants and treatment providers to surgical
interventions);
• incomplete outcome data; we coded a satisfactory level of
loss to follow-up for each outcome as:
◦ yes, if fewer than 20% of patients were lost to follow
up and reasons for loss to follow up were similar in both
treatment arms
◦ no, if more than 20% of patients were lost to follow up
or reasons for loss to follow up differed between treatment arms,
◦ unclear if loss to follow-up was not reported;
• selective reporting of outcomes;
• other possible sources of bias.
The risk of bias in non-randomised controlled trials was assessed
in accordance with the following four additional criteria.
Cohort selection
1. Were relevant details of criteria for assignment of patients to
treatments provided?
• Yes.
• No.
• Unclear.
2. Was the group of women who received the experimental
intervention (ultra-radical surgery) representative?
• Yes, if they were representative of women with advanced
stage ovarian cancer.
• No, if group of patients was selected.
• Unclear, if selection of group was not described.
3. Was the group of women who received the comparison inter-
vention (standard surgery) representative?
• Yes, if drawn from the same population as the exposed
cohort.
• No, if drawn from a different source.
• Unclear, if selection of group not described.
Comparability of treatment groups
1. Were there no differences between the two groups or were
differences controlled for, in particular with reference to age,
FIGO stage, histological cell type, differentiation, previous
treatment (neoadjuvant chemotherapy - responders versus non-
responders) and type of surgeon (gynae-oncologist,
gynaecologist, general surgeon).
• Yes, if at least three of these characteristics were reported
and any reported differences were controlled for.
• No, if the two groups differed and differences were not
controlled for.
• Unclear, if fewer than three of these characteristics were
reported even if there were no other differences between the
groups, and other characteristics were controlled for.
The risk of bias tool was applied independently by two reviewers
(CA, KC) and differences resolved by discussion or by appeal to a
third reviewer (AB). Results were presented in a risk of bias graph.
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Measures of treatment effect
We used the following measures of the effect of treatment.
• For time to event data, we used the hazard ratio.
Dealing with missing data
We did not impute missing outcome data for any outcomes.
Data synthesis
We were unable to pool results in meta analyses as only one study
met our inclusion criteria. Therefore it was not possible to assess
heterogeneity between results of studies and we were unable to
assess reporting biases using funnel plots or conduct any sub group
or sensitivity analyses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search strategy identified 2007 references in MEDLINE,
1740 in EMBASE, 320 in CENTRAL and 12 in the Specialised
Register. When the search results were merged into EndNote and
duplicates were removed, 2965 unique references remained. The
title and abstract screening identified 22 references as potentially
eligible. The full text screening excluded 21 of these for the reasons
described in the table Characteristics of excluded studies. The one
remaining reference (Aletti 2006) reported a study that met our
inclusion criteria and is described in the table Characteristics of
included studies.
Searches of the grey literature did not identify any additional rel-
evant studies.
Included studies
Design
The one included study (Aletti 2006) reported a retrospective anal-
ysis of 194 patients from the Mayo clinic in Rochester, Minnesota
who had ovarian cancer and received either ultra-radical (n = 83
(43%)) or standard surgery (n = 111 (57%)). Only women with
FIGO stage IIIC disease were included in the study, which im-
plies that these women had abdominal tumour deposits of greater
than 2 cm and positive retroperitoneal or inguinal lymph nodes.
The study also reported the results of 144 of these women with
carcinomatosis (n = 68 (47%) and n = 76 (53%) in the ultra-
radical and standard surgery groups respectively). As the primary
objective of the study was to assess the benefits of tumour cytore-
duction, rather than the specific benefits of each type of surgery,
baseline demographics were not reported by surgical group.
Participants
The mean and median age at diagnosis of advanced epithelial
ovarian cancer for the entire study (n = 194)were 64.4 and 64 years
respectively (range 24 to 87). Themajority of patients had a serous
(126/194; 65%) histological tumour cell type, with endometrioid,
mixed and seroanaplastic amounting to most of the other tumour
cell types (52/194, 27%). Most patients had a grade III tumour
(180/194; 93%) and an ASA score of 2 or 3 (175/194; 90%). The
mean and median volume of ascites were 2076 ml and 1,000 ml
respectively (range: 0 to 12,000 ml).
Interventions
Initial surgerywas performed for diagnosis, staging and surgical cy-
toreduction. Surgery was classified as ultra-radical if any diaphrag-
matic surgery, bowel resection, splenectomy, or extensive abdomi-
nal peritoneal stripping or resection were performed. Surgery was
classified as standard if none of these procedures were performed,
but hysterectomy, complete omentectomy, stripping of pelvic peri-
toneum, or limited resection of peritoneal-based nodules was car-
ried out. Patients were first classified by the extent of peritoneal
dissemination. Those with tumour nodules diffusely covering the
majority of the bowel serosal surfaces and the parietal peritoneum
of the abdomen and pelvis were classified as having carcinomato-
sis.
The centre’s division of gynaecologic surgery contained a mixed
group of surgeons, some being more likely to carry out ultra-
radical surgery but all sharing a uniform referral base with similar
patient demographics, practicing at a single institution where each
surgeon had access to identical services and nursing support.
It was reported that: “Radical procedures were performed at the
same rate regardless of age (49% for age < 65 years versus 51%
for age > 65 years; P= 0.45). Patients with better ASA scores (1
or 2 versus 3 or 4) were more likely to have aggressive procedures
performed (59% versus 36%, respectively; P= 0.005), which im-
plies the overall medical condition of the patient at least partially
influences the decision to perform aggressive surgery”. However,
the numbers of women in each surgical group were not reported.
For further details see the table Characteristics of included studies.
The mean and median length of follow up were 3.5 years and 2.7
years respectively (range 0.02 to 10.5 years).
Outcomes reported
The study reported disease specific survival and perioperative mor-
tality. Disease specific survival and peri-operative mortality, de-
fined as death within 2 weeks following surgery, are important
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factors used to assess the risks of a particular surgical intervention
and the level of surgical expertise. In this review, we have used
’death within 30 days’ as a secondary outcomemeasure because this
cut-off has been widely used in the literature and would include
patients who die of complications directly related to surgery that
may only manifest 1 to 2 weeks after surgery. No other side effects
were reported. Progression-free survival, overall survival and QoL
were not reported. The paper used the term ’disease specific overall
survival’ to include death from disease or surgical treatment.
Although not reported in the original paper, the authors provided
estimates of the HR from a multivariable Cox model, comparing
death from advanced ovarian cancer in the ultra-radical surgery
arm with that in the standard surgery arm for all 194 women and
for the 144 women with carcinomatosis. The model for all 194
women was adjusted for: age (continuous), age ( > 65 years versus
≤ 65 years), ASA score (3 or 4 versus 1 or 2), carcinomatosis (Yes,
No), mesenteric involvement (Yes, No), diaphragmatic involve-
ment (Yes, No), ascites (> 1000 ml versus ≤1000 ml), residual
disease (<1 cm versus 0 cm, 1 to 2 cm versus 0 cm, > 2 cm versus
0 cm) and operative time (> 150 min versus ≤150 minutes); the
model for 144 women with carcinomatosis was adjusted for: age
(continuous), ASA score (3 or 4 versus 1 or 2), histologic grade
(3 versus 1 or 2), residual disease (<1 cm versus 0 cm, 1 to 2 cm
versus 0 cm, >2 cm versus 0 cm) and operative time (> 150 min
versus ≤ 150 min).
Excluded studies
Twenty-one references were excluded after obtaining the full text
for the following reasons:
• In six studies (Aletti 2009a; Aletti 2009b; Bertelsen 1990;
Eisenkop 2001; Eisenkop 2003; Wimberger 2007), a comparison
of ultra-radical and standard surgery was not possible.
• Patients in the comparison (standard surgery) group also
had extensive bowel surgery (which is classified as ultra-radical)
in seven studies (Aletti 2006b; Chi 2004; Eisenhauer 2006;
Eisenkop 1993; Eisenkop 1998; Kommoss 2010; Kuhn 1998),
diaphragmatic stripping in two studies (Tsolakidis 2010a;
Tsolakidis 2010b) and extensive upper abdominal surgery in the
Chi 2009 study.
• In three studies (Aletti 2006a; Cai 2007; Eisenkop 2006),
the intervention was a specific form of ultra-radical surgery but it
was unclear as to whether those in the comparison group received
a different form of ultra-radical surgery or standard surgery.
• In the Bristow 1999 study, patients with recurrent disease
were included, whereas in the von Hugo 1989 study it was
unclear whether women with recurrent disease were included.
For further details of all excluded studies see the table
Characteristics of excluded studies.
Risk of bias in included studies
The one included study (Aletti 2006) was at high risk of bias. It sat-
isfied only four of the ten criteria that we used to assess risk of bias
(see Figure 1). It reported a retrospective analysis so the method
of sequence generation and concealment of allocation (which are
relevant only to RCTs) were deemed to be unsatisfactory, and ret-
rospective group allocation was not based on an intention to treat
basis. It did not report details of assignment of patients to groups.
It was unclear whether or not the two treatment groups were rep-
resentative of women with advanced epithelial ovarian cancer as
they only included women with stage IIIC disease. We deemed
loss to follow up to be satisfactory as all women were analysed. The
study did not report whether the outcome assessors were blinded.
A multivariate analysis was performed, adjusting for important
prognostic factors that were significant predictors of survival in
univariate analyses, so the two groups were deemed to be com-
parable. The authors reported disease specific survival rather than
overall survival which is a more appropriate and reliable outcome
measure and did not report any QoL data or state if there were
any pre-defined outcome measures prior to data analysis, so it is
possible that the outcomes may have been selectively reported.
There was an additional source of potential bias as themultivariate
analysis adjusted for variables that were measured after the time
origin in some of the analyses, namely extent of residual disease
and operative time (Altman 1995).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Effects of interventions
Disease specific survival
Overall, optimal cytoreduction (< 1 cm) was achieved in 67% of
the 194 women enrolled in the study. Women who had ultra-
radical surgery had better disease specific survival than those who
underwent standard surgery, although the difference between the
groups was not statistically significant. After adjustment for age,
ASA score, carcinomatosis, mesenteric involvement, diaphrag-
matic involvement, ascites, residual disease and operative time,
the hazard ratio (HR) comparing the risk of death from advanced
epithelial ovarian cancer in women receiving ultra-radical surgery
with the risk in women receiving standard surgery was 0.64 95%
CI 0.40 to 1.04. The unadjusted estimate was similar in magni-
tude and also not statistically significant (HR = 0.72, 95%CI 0.51
to 1.02), which suggests that the two groups were well balanced
at baseline.
Among the 144 women with carcinomatosis, univariate analysis
using the log-rank test indicated that the only significant predictors
of disease specific survival were the type of surgery, age (continu-
ous), ASA score, residual disease and operative time. Multivariate
analysis using Cox regression found that women who underwent
ultra-radical surgery had significantly less chance of death from
ovarian cancer than women who underwent standard surgery, af-
ter adjustment for grade and for all factors that were significant
in univariate analysis (HR = 0.64, 95% CI 0.41 to 0.98). The
unadjusted estimate was more extreme and, likewise, statistically
significant (HR = 0.43, 95% CI 0.29 to 0.62).
Because of the potential effect of performance status on disease
specific overall survival, the authors did a further subgroup analysis
on 72 women with carcinomatosis, who had ASA grades of 1 and
2, and found a better outcome in those undergoing ultra-radical
surgery: five-year disease specific overall survival was 46% and
13% (P < 0.001) in women undergoing ultra-radical and standard
surgery respectively.
Perioperative mortality
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In the standard surgery group, three women died within 30 days of
surgery and there were no reported cases of perioperative mortality
in the ultra-radical surgery group.
D I S C U S S I O N
Summary of main results
We found only one study (Aletti 2006) that met our inclusion cri-
teria. It reported retrospective data for 194 women with stage IIIC
disease who underwent either ultra-radical or standard surgery,
and also analysed a subset of 144 of these women with carcino-
matosis, that is the highest volume of disease. The criteria for as-
signment of women to the two surgical procedures were not re-
ported other than stating that some surgeons within the centre
were more inclined to perform ultra-radical surgery than other
surgeons within the same centre. The assignment of patients into
the ultra-radical and standard surgery groups was made depend-
ing on the extent of the surgery performed. Three women who
underwent standard surgery died within 30 days of surgery, while
there were no perioperative deaths in women who underwent ul-
tra-radical surgery. After adjustment for important prognostic fac-
tors, multivariate analysis of all 194 patients found that women
who underwent ultra-radical surgery had similar disease specific
survival to those who underwent standard surgery (HR = 0.64,
95% CI 0.40 to 1.04). As women with stage IIIC ovarian cancer
represent a heterogenous group in terms of extent of disease. the
authors performed a sub group analysis restricted to women with
carcinomatosis. These women had a similar extent of disease, and
the study found that the estimated benefit of ultra-radical surgery
was similar but the results were statistically significant (HR = 0.64,
95% CI 0.41 to 0.98). This supports the hypothesis that ultra-
radical surgery can negate the effect of aggressive tumour biology.
A further subgroup analysis on 72 women with carcinomatosis
who had ASA grades of 1 and 2 confirmed the better outcome in
those undergoing ultra-radical than standard surgery, suggesting
that the improved outcomes in the ultra-radical group were un-
likely to be related to better overall health of these women.
Overall completeness and applicability of
evidence
Overall, the quality of the evidence was low (GRADE Working
Group) because the review found only one relevant non-ran-
domised study. This severely limits the conclusions that can be
drawn. The one included study did not address many of the ob-
jectives of the review. Other adverse events were not documented
and QoL was not reported.
The one included study (Aletti 2006) reported disease specific
overall survival, which includes deaths from ovarian cancer and
deaths from surgical treatment.However, all causemortality (over-
all survival) - our primary outcome of interest - was not reported.
When trying to assess the effect of ultra-radical against standard
surgery, the extent of residual disease is likely to be a consequence
of the initial extent of disease (e.g. the pattern rather than the
stage and bulk) as well as whether ultra-radical or standard surgery
was performed (e.g. the degree of surgical radicality). Adjusting
for extent of residual disease in the multivariate model is likely to
dilute the estimate of the effect of the type of surgery. This me-
diating variable is on the causal pathway between type of surgery
and outcome. Likewise, operative time is also a mediating vari-
able. Prognostic factors that are known (or could in principle be
known) before the operation is performed for example age, ASA
score, carcinomatosis, mesenteric involvement, diaphragmatic in-
volvement, ascites, are moderating variables and it is completely
valid to adjust for them. Indeed, it is necessary to adjust for them
because they are probably confounded with assignment to treat-
ment group.
Another flaw in the study is the assumption that inwomenwith ex-
tensive disease inwhom complete cytoreductionwould not be pos-
sible even with ultra-radical surgery (e.g. women with porta hep-
atis disease or extensive mesenteric involvement) would not have
undergone extensive debulking surgery, which also contributes to
the risk of bias in this study. Furthermore, surgeons are more likely
to perform ultra-radical surgery if the woman is fitter (partially
reflected in the ASA grade), and also if the surgeon has a greater
level of expertise. For this reason the authors carried out another
sub-group analysis on 72 women. The vast majority of women in
this study (182/194; 94%) had ASA grades between 1 to 3.
Women with advanced ovarian cancer are generally in poor health
and have a relatively short life expectancy. A good QoL after treat-
ment is therefore an important issue in this group of women, but
unfortunately this review was unable to assess this important out-
come as it was not reported.
Quality of the evidence
The one included study analysed a reasonable number of women
(n = 194), but was at high risk of bias, largely because it was a
retrospective study. Patient characteristics were not reported by
surgical arm so it was not possible to assess whether the groups
receiving different types of surgery were similar prior to surgery.
However, univariate analysis showedwhich factors were important
predictors of disease specific survival on their own and analysis of
the type of surgery that adjusted for these prognostic factors gave
similar results to the unadjusted results, suggesting that prognostic
factors were probably balanced between surgical groups. However,
it is possible that factors not significant in univariate analysis could
influence the estimates of effect in the multivariate model. Fur-
thermore, the dichotomy of some of the co-variates is also ques-
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tionable and variables that were not considered in the analysis,
such as co-morbidities and ethnicity, could also influence results.
Potential biases in the review process
A comprehensive search was performed, including a thorough
search of the grey literature and all studies were sifted and data
extracted independently by at least two review authors. The re-
view included non-randomised studies and was not restricted to
RCTs which provide the strongest level of evidence available. We
made every attempt to minimise bias in the review process. We
anticipated that selection bias was likely to be a real problem due
to the non-randomised assignment of patients to surgery as it was
likely that treatment allocation depended on the clinical indica-
tion and the level of surgical expertise available. We attempted to
minimise this bias by only including RCTs or quasi-RCTs or non-
randomised studies of sufficient quality that adjusted for baseline
differences between the groups receiving different types of surgery.
Unfortunately we were only able to include one study of such
quality that met the inclusion criteria.
A further threat to the validity of the review is likely to be the
possibility of publication bias. Studies that did not find a statisti-
cally significant difference between treatments may not have been
published. We were unable to assess this possibility as the analysis
was restricted to a single study.
Agreements and disagreements with other
studies or reviews
One of the excluded studies (Wimberger 2007) evaluated the im-
pact of different prognostic factors for surgical outcome and evalu-
ated the impact of surgical outcome on survival in womenwith ad-
vanced stage ovarian cancer. In this prospective study, 798 women
with FIGO IIB-IV disease from 136 centres within Germany were
operated on and then randomised to receive either cisplatin and
paclitaxol or carboplatin and paclitaxol chemotherapy. Complete
surgical datawere obtained from761women andwere analysed us-
ingmultivariable logistic regression. Complete cytoreduction with
nomacroscopic residual tumourwas achieved in 29.8%ofwomen,
with a significant improved overall survival compared to women
with visible, including small remaining disease (P <0.0001). In
women with FIGO stages IIIC and IV, complete cytoreduction
was less likely in older women, those with a higher pre-operative
tumour load, worse performance status, and peritoneal carcino-
matosis. FIGO stage was not an independent factor for complete
cytoreduction in this group of women. The authors identified a
subgroup of 71 centres (type A)which demonstrated the capability
of performing ultra-radical surgery having carried out pelvic and/
or para-aortic lymphadenectomy and peritoneal stripping in at
least one of the enrolled patients in the study. This group included
534 (69.8%) women. The remaining 65 centres were identified
as type B centres and treated 227 women. A higher percentage
of patients with worse performance status were treated in type A
centres (53.9% versus 43.6%, P = 0.009). Type A centres more of-
ten achieved complete cytoreduction compared to type B centres
(32.8% versus 22.9%, P = 0.007). Treatment in type A centres
was associated with greater overall survival compared to treatment
in type B centres (45.2 months versus 35 months, p = 0.045).
Their results suggest an advantage for aggressive primary surgery
and complete cytoreduction inwomenwithmore advanceddisease
when operated on in experienced centres. Although this study was
excluded from the review because the comparative groups were by
treatment centres that contained a mixed case load of ultra-radical
and standard surgery, it does provide some evidence that aggressive
primary cytoreductive surgery can negate the effects of aggressive
tumour biology in advanced ovarian cancer, with a subsequent
improvement in overall survival.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found only low quality evidence comparing ultra-radical and
standard surgery in women with advanced ovarian cancer and
carcinomatosis. Although the evidence suggested that ultra-radical
surgery may result in better survival, it was based on one study at
high risk of bias. It was unclear whether there were any differences
in progression-free survival, QoL and morbidity between the two
groups. the cost-effectiveness of this intervention has not been
investigated.
We are, therefore, unable to reach definite conclusions about the
relative benefits and adverse effects of the two types of surgery.
Implications for research
To date, most studies of ultra-radical (extensive) surgery for ad-
vanced stage ovarian cancer have assessed residual disease as an
outcome rather than survival. Other studies which have assessed
the role of ultra-radical surgery have not compared it with standard
surgery and have included women with recurrent disease, making
this a heterogeneous group of women and hence limiting the in-
ferences that can be made about the role of ultra-radical surgery.
In order to determine the role of ultra-radical surgery in the man-
agement of advanced stage ovarian cancer, it should be compared
with standard surgery in women undergoing primary cytoreduc-
tive surgery for extensive disease, ideally in a sufficiently powered
randomised controlled trial. However, it is acknowledged that
there may be some difficulties in designing such trials.
If randomised controlled trials are not feasible, high quality non-
randomised studies should be designed. Such studies should in-
clude all patients treated in several centres in a specified time pe-
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riod; data collection should use agreed criteria for prognostic fac-
tors, including the experience of the treating surgeon; multivari-
able analysis should allow for baseline prognostic factors but not
for variables (such as extent of residual disease or operating time)
that were recorded after women were assigned to surgical groups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aletti 2006
Methods Retrospective cohort study of consecutive patients identified from surgical records
Surgery carried out at Mayo Clinic.
Participants Patients with FIGO stage IIIC ovarian cancer, where disease status was extracted from
surgical exploration notes
The mean and median age at study entry was 64.4 and 64 years respectively (range 24
to 87)
All women presented with FIGO stage IIIC: 194/194 (100%)
Tumor cell type: Serous 126 (64.9%), Mucinous: 4 (2.1%), Endometrioid: 18 (9.3%),
Clear cell: 7 (3.6%), Mixed: 17 (8.8%), Seroanaplastic: 17 (8.8%), Mullerian origin: 2
(1%)
Tumor grade: 1: 1 (0.5%), 2: 13 (6.7%), 3: 180 (92.8%)
ASA score: 1: 7 (3.6%), 2: 87 (44.8%), 3: 88 (45.4%), 4: 7 (3.6%), Unknown: 5
(2.6%)
Ascites: Mean: 2076 ml, Median 1,000 ml, (Range: 0 to 12,000 ml)
Extent of disease: carcinomatosis: 144 (74.2%), Diaphragm involvement: 137 (70.6),
mesentery: 138 (71.1), cul-de-sac: 163 (84), omentum 168: (86.6), Ascites 160: (82.5)
Baseline details for 144 women with carcinomatosis were not reported
Interventions Initial surgery was performed for diagnosis, staging, and surgical cytoreduction
Intervention:
Ultraradical surgery: If any diaphragmatic surgery, bowel resection, splenectomy, or
extensive abdominal peritoneal stripping or resection
Comparison:
Standard surgery: Hysterectomy, complete omentectomy, stripping of pelvic peri-
toneum, or limited resection of peritoneal-based nodules
Outcomes Disease specific overall survival
Perioperative mortality
Notes Mean and median length of follow up was 3.5 years and 2.7 years respectively (range,
0.02 to 10.5 years)
Patients were first classified by the extent of peritoneal dissemination. Those with tumour
nodules diffusely covering the majority of the bowel serosa surfaces and the parietal
peritoneum of the abdomen and pelvis were classified as having carcinomatosis
Inmultivariate analysis, only residual disease and radical surgerywere independent factors
predicting patient survival (Table 4)
“When examining the effect of radical surgery on all patients with carcinomatosis (n =
144), we observed an improved disease-specific overall survival rate (38% versus 9%; log-
rank test, P= 0.001) favouring patients who underwent radical procedures versus non-
radical procedures (Fig. 3)”
“Radical procedures were performed at the same rate regardless of age (49% for age 65
years versus 51% for age 65 years; P .45). Patients with better ASA scores (1 or 2 versus
3 or 4) were more likely to have aggressive procedures performed (59% versus 36%,
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Aletti 2006 (Continued)
respectively; P .005), which implies the overall medical condition of the patient at
least partially influences the decision to perform aggressive surgery”
“The 5-year disease-specific overall survival ratewas 46%comparedwith 13%for patients
with radical and non-radical surgeries, respectively (log-rank test, P.001; Fig. 4A)”
“The rate of optimal resection (residual disease 1 cm) was 84.5% compared with 51%
on the basis of surgeon tendency to use radical procedures”
“Our division of gynaecologic surgery shares a uniform referral base with similar patient
demographics, and we practice at a single institution where each surgeon has access to
identical services and nursing support”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Retrospective non-randomised study.
Allocation concealment (selection bias) High risk Retrospective cohort study of patients iden-
tified from surgical records
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk % analysed: 194/194 (100%) of all women
eligible for analysis, and 144/144 (100%)
for women with carcinomatosis
Selective reporting (reporting bias) High risk Disease specific survival is not a good out-
come measure to use for several reasons,
namely the coding of death certificates is
notoriously error-prone. If someone dies
because of the treatment they receive, this
may not be counted as a death from OC.
But it is just as important to the patient as
a death from OC and the evaluation of the
relative benefits of the treatments should
include these deaths. The study authors
would have had access to data for death
from all causes
Other bias High risk There is a serious problem in the mul-
tivariate analysis. It adjusted for variables
that were measured after the time origin,
namely extent of residual disease and oper-
ative time (Altman 1995).
Details of assignment of patients reported? High risk Not reported.
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Aletti 2006 (Continued)
Representative ultra-radical surgery group? Unclear risk All patients had stage IIIC disease so may
not have been representative of all women
with advanced stage disease (III and IV)
Representative standard surgery group? Unclear risk All patients had stage IIIC disease so may
not have been representative of all women
with advanced stage disease (III and IV)
Comparability of groups? Low risk “Significant variables from the univariate
analysis were included in the multivariable
model”
Multivariate Cox model included type
of surgery, residual disease, age, ASA
score, carcinomatosis, bowel mesentery, di-
aphragm, ascites and operative time
The unadjusted HR for overall survival was
similar to themultivariate one, so it is likely
that the two groups were well balanced at
baseline, as most prognostic factors were
statistically significant in univariate analy-
ses
Multivariate analysis of subset of 144 pa-
tients with carcinomatosis also used adjust-
ment for significant variables in univariate
analyses
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aletti 2006a Interventionwas ultra-radical (removal of tumour fromdiaphragm), but unclear as towhether those in comparison
group received different form of ultra-radical surgery
Aletti 2006b Patients in comparison standard surgery group also had extensive bowel surgery which is ultra-radical. It was also
unclear whether women with recurrent disease were included
Aletti 2009a Comparison of ultra-radical versus standard surgery groups not possible - low complexity scores also included
possible small bowel resection
Aletti 2009b Comparison of ultra-radical versus standard surgery groups not possible - low complexity scores also included
possible small bowel resection
Bertelsen 1990 Comparison of ultra-radical versus standard surgery groups not possible. It was also unclear whether women with
recurrent disease were included
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(Continued)
Bristow 1999 Patients with recurrent disease also included.
Cai 2007 Comparisons were made between bowel resection versus no bowel resection regardless of the nature of surgery,
so those in the no bowel resection group may have still received a form of ultra-radical surgery. It was also unclear
whether women with recurrent disease were included
Chi 2004 Patients in comparison standard surgery group also had extensive bowel surgery which is ultra-radical. It was also
unclear whether women with recurrent disease were included
Chi 2009 Comparison between standard surgery and ultra-radical surgery groups not possible as all women underwent
extensive upper abdominal surgery
Eisenhauer 2006 Patients in comparison standard surgery group also had extensive bowel surgery which is ultra-radical. Also
unclear if women with recurrent disease included
Eisenkop 1993 Patients in comparison standard surgery group also had extensive bowel surgery and/or diaphragmatic stripping
which is ultra-radical. It was also unclear whether women with recurrent disease were included
Eisenkop 1998 Patients in comparison standard surgery group also had extensive bowel surgery and/or diaphragmatic stripping
which is ultra-radical. Patients with recurrent disease were also included
Eisenkop 2001 Comparison of ultra-radical versus standard surgery groups not possible.
Eisenkop 2003 Comparison of ultra-radical versus standard surgery groups not possible. Patients with recurrent disease were also
included
Eisenkop 2006 Comparisons were made between splenectomy versus no splenectomy regardless of the nature of surgery, so those
in the no splenectomy group may have still received a form of ultra-radical surgery. Patients with recurrent disease
were also included
Kommoss 2010 Comparison between groups not possible as both standard surgery group also included patients undergoing bowel
resection
Kuhn 1998 Patients in comparison standard surgery group also had extensive bowel surgery and/or diaphragmatic stripping
which is ultra-radical. Patients with recurrent disease were also included
Tsolakidis 2010a Comparison between ‘standard surgery’ and ‘ultra-radical surgery’ groups not possible as all women underwent
diaphragmatic stripping
Tsolakidis 2010b Comparison between standard surgery and ultra-radical surgery groups not possible as all women underwent
diaphragmatic stripping
von Hugo 1989 Unclear if women with recurrent disease were included.
Wimberger 2007 Comparison of ultra-radical versus standard surgery groups not possible, as the comparative groups include
patients who had both types of surgery
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Medline Ovid 1950 to November week 3, 2010
1. exp Ovarian Neoplasms/
2. (ovar* adj5 (cancer* or neoplas* or carcinom* or malignan* or tumor* or tumour*)).mp.
3. 1 or 2
4. exp Surgical Procedures, Operative/
5. surg*.mp.
6. surgery.fs.
7. 4 or 5 or 6
8. debulk*.mp.
9. cytoreduc*.mp.
10. (ultraradical or ultra-radical or ultra radical).mp.
11. exp Omentum/
12. omentum.mp.
13. bowel.mp.
14. abdom*.mp.
15. exp Spleen/
16. spleen.mp.
17. exp Liver/
18. liver.mp.
19. exp Diaphragm/
20. diaphragm*.mp.
21. exp Lymph Nodes/
22. (lymph adj node*).mp.
23. exp Peritoneum/
24. peritone*.mp.
25. exp Urinary Tract/
26. (urinary adj tract).mp.
27. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. 7 and 27
29. exp Splenectomy/
30. splenectomy.mp.
31. exp Hysterectomy/
32. (abdom* adj5 hysterectomy).mp.
33. abdominohysterectomy.mp.
34. exp Lymph Node Excision/
35. (lymph adj node adj excision).mp.
36. (bilateral adj salpingo adj oophorectomy).mp.
37. omentectomy.mp.
38. exp Surgical Stomas/
39. stoma.mp.
40. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
19Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
41. 28 or 40
42. 3 and 41
43. “randomized controlled trial”.pt.
44. “controlled clinical trial”.pt.
45. randomized.ab.
46. randomly.ab.
47. trial.ab.
48. groups.ab.
49. exp Cohort Studies/
50. cohort*.mp.
51. (case adj series).mp.
52. 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
53. 42 and 52
54. Animals/
55. Humans/
56. 54 not (54 and 55)
57. 53 not 56
key: mp = title, original title, abstract, name of substance word, subject heading word
Appendix 2. EMBASE search strategy
Ovid Embase 1980 to 2010 week 47
1. exp Ovary Tumor/
2. (ovar* adj5 (cancer* or neoplas* or carcinom* or malignan* or tumor* or tumour*)).mp.
3. 1 or 2
4. exp Surgery/
5. surg*.mp.
6. su.fs.
7. 4 or 5 or 6
8. debulk*.mp.
9. cytoreduc*.mp.
10. (ultraradical or ultra-radical or ultra radical).mp.
11. exp Omentum/
12. omentum.mp.
13. bowel.mp.
14. abdom*.mp.
15. exp Spleen/
16. spleen.mp.
17. exp Liver/
18. liver.mp.
19. exp Diaphragm/
20. diaphragm*.mp.
21. exp Lymph Node/
22. (lymph adj node).mp.
23. exp Peritoneum/
24. peritone*.mp.
25. exp Urinary Tract/
26. (urinary adj tract).mp.
27. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. 7 and 27
29. exp Splenectomy/
30. splenectomy.mp.
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31. exp Hysterectomy/
32. (abdom* adj5 hysterectomy).mp.
33. abdominohysterectomy.mp.
34. exp Lymphadenectomy/
35. (lymph adj node adj excision).mp.
36. (bilateral adj salpingo adj oophorectomy).mp.
37. omentectomy.mp.
38. exp Stoma/
39. stoma.mp.
40. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. 28 or 40
42. 3 and 41
43. exp Controlled Clinical Trial/
44. randomized.ab.
45. randomly.ab.
46. trial.ab.
47. groups.ab.
48. exp Cohort Analysis/
49. cohort*.mp.
50. (case adj series).mp.
51. 50 or 49 or 46 or 45 or 43 or 44 or 48 or 47
52. 42 and 51
53. exp Animal/
54. Human/
55. 53 not (53 and 54)
56. 52 not 55
key: mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name
ab=abstract
fs=floating subheading
Appendix 3. CENTRAL search strategy
CENTRAL Issue 4, 2010
1. MeSH descriptor Ovarian Neoplasms explode all trees
2. ovar* near/5 (cancer* or neoplas* or carcinom* or malignan* or tumor* or tumour*)
3. (#1 OR #2)
4. MeSH descriptor Surgical Procedures, Operative explode all trees
5. surg*
6. Any MeSH descriptor with qualifier: SU
7. (#4 OR #5 OR #6)
8. debulk*
9. cytoreduc*
10. ultradical or ultra-radical or ultra radical
11. MeSH descriptor Omentum explode all trees
12. omentum
13. bowel
14. abdom*
15. MeSH descriptor Spleen explode all trees
16. spleen
17. MeSH descriptor Liver explode all trees
18. liver
19. MeSH descriptor Diaphragm explode all trees
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20. diaphragm*
21. MeSH descriptor Lymph Nodes explode all trees
22. lymph next node*
23. MeSH descriptor Peritoneum explode all trees
24. peritone*
25. MeSH descriptor Urinary Tract explode all trees
26. urinary next tract
27. (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
OR 23 OR #24 OR #25 OR #26)
28. (#7 AND #27)
29. MeSH descriptor Splenectomy explode all trees
30. splenectomy
31. MeSH descriptor Hysterectomy explode all trees
32. abdom* near/5 hysterectomy
33. abdominohysterectomy
34. MeSH descriptor Lymph Node Excision explode all trees
35. lymph next node next excision
36. bilateral next salpingo next oophorectomy
37. omentectomy
38. MeSH descriptor Surgical Stomas explode all trees
39. stoma
40. (#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39)
41. (#28 OR #40)
42. (#3 AND #41)
WH A T ’ S N E W
Last assessed as up-to-date: 2 March 2011.
Date Event Description
28 July 2011 Amended Author contact details updated
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 4, 2011
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added the following study constraint in the Types of studies section, as it was apparent that selection bias would have been
problematic.
In order to minimise selection bias, we decided to include only studies that used statistical adjustment for baseline case mix (for example
age, performance status, grade, etc) using multivariate analyses.
We removed discussion of unadjusted results from the data synthesis, subgroup analysis and investigation of heterogeneity and sensitivity
analysis sections as we do not plan to use unadjusted results in future updates due to the risk of selection bias.
Only one study met the inclusion criteria for the review and this did not report dichotomous or continuous outcomes and we were
unable to use the methods specified for a meta analysis. Should more studies be identified for updates of the review, the following
methods will be employed.
Data extraction and management
Data on outcomes will be extracted as below.
• For time to event data (overall survival), we extracted the log of the hazard ratio (HR) and its standard error from trial reports; if
these were not reported, we attempted to estimate the log (HR) and its standard error using the methods of Parmar 1998.
• For dichotomous outcomes (e.g. adverse events or deaths, if it was not possible to use a hazard ratio), we will extract the number
of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed at endpoint, in order
to estimate a risk ratio.
• For continuous outcomes (e.g. QoL measures), we will extract the final value and standard deviation of the outcome of interest
and the number of patients assessed at endpoint in each treatment arm at the end of follow up, in order to estimate the mean
difference between treatment arms and its standard error.
Measures of treatment effect
We will use the following measures of the effect of treatment.
• For dichotomous outcomes, we will use the risk ratio.
• For continuous outcomes, we will use the mean difference between treatment arms.
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Dealing with missing data
We will not impute missing outcome data. For the primary outcome, if data are missing or only imputed outcome data are reported,
we will contact trial authors to request data on the outcomes among participants who were assessed.
Assessment of heterogeneity
Heterogeneity between studies will be assessed by visual inspection of forest plots, by estimation of the percentage heterogeneity between
trials which cannot be ascribed to sampling variation (Higgins 2003), by a formal statistical test of the significance of the heterogeneity
(Deeks 2001) and, if possible, by sub group analysis (see below). If there is evidence of substantial heterogeneity, the possible reasons
for this will be investigated and reported.
Assessment of reporting biases
Funnel plots corresponding to meta-analysis of the primary outcome will be examined to assess the potential for small study effects.
When there is evidence of small-study effects, publication bias will be considered as only one of a number of possible explanations. If
these plots suggest that treatment effects may not be sampled from a symmetric distribution, as assumed by the random-effects model,
sensitivity analysis will be performed using fixed-effects models.
Data synthesis
If sufficient clinically similar studies are available, their results will be pooled in a meta-analysis. Adjusted summary statistics will be
used.
• For time-to-event data, hazard ratios will be pooled using the generic inverse variance facility of RevMan 5.
• For any dichotomous outcomes, the relative risk will be calculated for each study and these will then be pooled.
• For continuous outcomes, the mean differences between the treatment arms at the end of follow up will be pooled if all trials
measured the outcome on the same scale, otherwise standardised mean differences will be pooled.
Random effects models with inverse variance weighting will be used for all meta-analyses (DerSimonian 1986).
Subgroup analysis and investigation of heterogeneity
Sub-group analysis will be performed, grouping the trials by:
• women who received neoadjuvant chemotherapy (responders versus non-responders);
• stage of disease (Stage III versus Stage IV, as progression-free survival and overall survival will differ).
Factors such as age, type of surgeon, length of follow up and adjusted/unadjusted analysis will be considered in interpretation of any
heterogeneity.
Sensitivity analysis
Sensitivity analysis will be performed excluding studies at high risk of bias.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Neoplasms, Glandular and Epithelial [pathology; surgery]; ∗Ovarian Neoplasms [pathology; surgery]; Neoplasm Invasiveness [pathol-
ogy]; Neoplasm Staging
MeSH check words
Adult; Female; Humans
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